Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-001437
Filing Date
2026-07-31
Accepted
2026-07-31 10:42:07
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5719
  Complete submission text file 0002100119-26-001437.txt   7485
Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Subject) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91591 | Film No.: 261226164
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G